A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

RCT (n=314) was terminated early, as the monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy vs placebo among hospitalised patients (improved sustained recovery) who had Covid-19 without end-organ failure.

New England Journal of Medicine